AstraZeneca Acquires Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal

The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.

AstraZeneca has strengthened its oncology pipeline through a licensing agreement worth up to $1.5 billion for global development and commercialisation rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), an oral targeted therapy for non-small-cell lung cancer (NSCLC).

The agreement includes a $600 million upfront payment, with Dizal eligible for a further $900 million in development and commercial milestones, alongside tiered royalties on future sales.

The deal gives AstraZeneca exclusive rights to develop and commercialise Zegfrovy outside existing arrangements, adding a potential new growth driver to its lung cancer portfolio.

Following the announcement, Dizal’s shares increased by nearly 20%.

What is Zegfrovy and How Does It Work?

Zegfrovy is an oral irreversible epidermal growth factor receptor (EGFR) inhibitor designed to target specific mutations found in NSCLC.

The therapy is currently approved in:

• China

• The United States
  

for adults with locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy.

EGFR exon 20 insertion mutations represent a challenging subset of lung cancer, with historically limited targeted treatment options compared with other EGFR-driven tumours.

AstraZeneca said the agreement will allow the companies to expand access to a targeted oral therapy for patients with significant unmet medical need.

Dave Fredrickson, executive vice-president of AstraZeneca’s oncology haematology business unit, said the deal would help bring a differentiated treatment option to patients with limited therapeutic choices worldwide.

Clinical Data Supporting Zegfrovy Approval

Zegfrovy’s existing approvals were supported by clinical data from multiple studies.

In China, approval was based on findings from the pivotal WU-KONG6 study, while the US approval was supported by data from the Phase I/II WU-KONG1 Part B trial.

The programme demonstrated activity in patients with EGFR exon 20 insertion-positive NSCLC following platinum-based chemotherapy, a population where treatment options remain limited.

The drug’s oral administration also differentiates it from some existing targeted approaches, potentially offering greater convenience for patients and healthcare providers.

AstraZeneca and Dizal Target Earlier-Line Lung Cancer Treatment

The latest deal comes as Dizal continues to evaluate Zegfrovy in earlier stages of NSCLC treatment.

The company has submitted regulatory applications in both China and the US seeking approval for first-line treatment in patients with EGFR exon 20 insertion mutations.

These applications are supported by data from the Phase III WU-KONG28 study.

If approved, Zegfrovy would enter a more competitive treatment setting, including against Johnson & Johnson’s Rybrevant (amivantamab-vmjw), a bispecific antibody already approved by the FDA for first-line treatment of EGFR exon 20 insertion-positive NSCLC in combination with chemotherapy.

The move into earlier treatment lines could significantly expand the commercial opportunity for Zegfrovy.

Why AstraZeneca Is Investing in Lung Cancer Innovation

Lung cancer remains one of the largest areas of focus within oncology, with targeted therapies becoming increasingly important as researchers identify more specific genetic drivers of disease.

AstraZeneca has built a strong position in lung cancer through medicines targeting different molecular pathways, including EGFR mutations.

The company’s oncology strategy has increasingly focused on precision medicine approaches that match treatments to specific patient characteristics.

Adding Zegfrovy could strengthen AstraZeneca’s ability to compete across different EGFR-mutated lung cancer populations while expanding its pipeline of oral targeted therapies.

The Growing Competition in EGFR-Driven NSCLC

The EGFR landscape continues to evolve as pharmaceutical companies develop therapies aimed at increasingly specific mutations.

While traditional EGFR inhibitors have transformed treatment for some NSCLC patients, exon 20 insertion mutations have remained more difficult to treat due to differences in receptor structure and drug response.

New therapies targeting these mutations are attempting to address this gap by offering more precise inhibition.

The success of Zegfrovy will depend on its ability to demonstrate durable clinical benefit, secure broader regulatory approvals and compete within an increasingly crowded precision oncology market.

Summary

AstraZeneca has secured global development and commercialisation rights to Dizal Pharmaceutical’s Zegfrovy in a deal potentially worth $1.5 billion.

The oral EGFR inhibitor is currently approved for previously treated patients with EGFR exon 20 insertion-positive NSCLC in China and the US.

With regulatory submissions underway for first-line treatment, Zegfrovy could become an important addition to AstraZeneca’s oncology portfolio as competition intensifies in targeted lung cancer therapies.

The agreement highlights the continued value of precision oncology assets as pharmaceutical companies look to strengthen their pipelines through strategic licensing deals.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com